Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Orforglipron is a small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist in clinical development for type 2 diabetes and weight management. Additional data on the efficacy and safety of orforglipron are needed. METHODS: In this phase 3, double-blind, placebo-controlled trial, we randomly assigned participants in a 1:1:1:1 ratio to receive orforglipron at one of three doses (3 mg, 12 mg, or 36 mg) or placebo once daily for 40 weeks. Participants had type 2 diabetes treated only with diet and exercise, a glycated hemoglobin level of at least 7.0% but no more than 9.5%, and a body-mass index (the weight in kilograms divided by the square of the height in meters) of at least 23.0. The primary end point was the change from baseline to week 40 in the glycated hemoglobin level. A key secondary end point was the percent change in body weight from baseline to week 40. RESULTS: A total of 559 participants underwent randomization. The mean glycated hemoglobin level at baseline was 8.0%. At week 40, the estimated mean change from baseline in the glycated hemoglobin level was -1.24 percentage points with the 3-mg dose, -1.47 percentage points with the 12-mg dose, -1.48 percentage points with the 36-mg dose, and -0.41 percentage points with placebo. All three doses of orforglipron were superior to placebo with respect to the primary end point; the estimated mean difference from placebo was -0.83 percentage points (95% confidence interval [CI], -1.10 to -0.56) with the 3-mg dose, -1.06 percentage points (95% CI, -1.33 to -0.79) with the 12-mg dose, and -1.07 percentage points (95% CI, -1.33 to -0.81) with the 36-mg dose (P<0.001 for all comparisons). The mean glycated hemoglobin level at week 40 was 6.5 to 6.7% with orforglipron. The percent change in body weight from baseline to week 40 was -4.5% with the 3-mg dose, -5.8% with the 12-mg dose, -7.6% with the 36-mg dose, and -1.7% with placebo. The most common adverse events were mild-to-moderate gastrointestinal events, most of which occurred during dose escalation. No episodes of severe hypoglycemia were reported. Permanent discontinuation of orforglipron or placebo due to adverse events occurred in 4.4 to 7.8% of participants receiving orforglipron and 1.4% of participants receiving placebo. CONCLUSIONS: In adults with early type 2 diabetes, orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks. (Supported by Eli Lilly; ACHIEVE-1 ClinicalTrials.gov number, NCT05971940.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In people with type 2 diabetes, the maximum reduction in HbA 1c with orforglipron was 1•1% (0•8-1•3) or 12 (9-14) mmol/mol for 36 mg per day (placebo-corrected), along with a bodyweight reduction of up to 5•9% (4•4-7•4) versus baseline.122”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [122]
In the citing paper
“the dose-escalation period (up to 20 weeks), but remained high (nausea in up to 12 % [vs up to 28% in phase 2], vomiting in up to 14% [vs up to 36%], and drug discontinuation due to adverse events in up to 8% [vs up to 19%] of the exposed participants).122,143”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [122]
In the citing paper
“Orforglipron 3-36 mg once daily vs placebo over 40 weeks Up to 5•9% (4•4-7•4) with 36 mg/day Up to 1•07% (0•81-1•33) with highest dose Low drug discontinuation due to adverse events (<5•7%); weight plateau not reached Rosenstock et al (2025) 122 (ACHIEVE-1)”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [122]
In the citing paper
“Resistance training helps mitigate these effects by maintaining muscle mass and preserving metabolic capacity, including mitochondrial function and glucose utilization.”
From Weight maintenance after discontinuation of GLP-1 therapies (2026) · cites this paper as [78]
In the citing paper
“Tolerability may also be improved through patient education, gradual dose escalation, and proactive side-effect management, while newer formulations, including longer-acting and oral agents, may reduce treatment burden and improve adherence.78,106,107”
From Weight maintenance after discontinuation of GLP-1 therapies (2026) · cites this paper as [78]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745
Transcellular Stomach Absorption of a Derivatized Glucagon-Like Peptide-1 Receptor Agonist
Buckley, S. T., Bækdal, T. A., Vegge, A., Maarbjerg, S. J., Pyke, C., Ahnfelt-Rønne, J., Madsen, K. G., Schéele, S. G., Alanentalo, T., Kirk, R. K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar7047 · Cited by 553
Aroda, V. R., Rosenstock, J., Terauchi, Y., Altuntas, Y., Lalic, N. M., Morales Villegas, E. C., Jeppesen, O. K., Christiansen, E., Hertz, C. L., Haluzík, M., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0749 · Cited by 493
Self-citationAmerican Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s008 · Cited by 236
Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist
Kawai, T., Sun, B., Yoshino, H., Feng, D., Suzuki, Y., Fukazawa, M., Nagao, S., Wainscott, D. B., Showalter, A. D., Droz, B. A., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2014879117 · Cited by 231
Frias, J. P., Hsia, S., Eyde, S., Liu, R., Ma, X., Konig, M., Kazda, C., Mather, K. J., Haupt, A., Pratt, E., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01302-8 · Cited by 184
Self-citationBattle of GLP-1 delivery technologies
Yu, M., Benjamin, M. M., Srinivasan, S., Morin, E. E., Shishatskaya, E. I., Schwendeman, S. P., & Schwendeman, A. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.009 · Cited by 180
Saxena, A. R., Gorman, D. N., Esquejo, R. M., Bergman, A., Chidsey, K., Buckeridge, C., Griffith, D. A., & Kim, A. M. (2021) · Nature Medicine · doi:10.1038/s41591-021-01391-w · Cited by 156
Boye, K., Ross, M., Mody, R., Konig, M., & Gelhorn, H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14244 · Cited by 88
Cited by
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
Horn, D. B., Ryan, D. H., Kis, S. G., Alves, B., Mu, Y., Kim, S. G., Aberle, J., Bain, S. C., Allen, S., Sarker, E., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02165-8 · Cited by 70
The expanding landscape of GLP-1 medicines
Drucker, D. J. (2026) · Nature Medicine · doi:10.1038/s41591-025-04124-5 · Cited by 82
New Molecules and Indications for GLP-1 Medicines
Gonzalez-Rellan, M. J., & Drucker, D. J. (2025) · JAMA · doi:10.1001/jama.2025.14392 · Cited by 50
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf036 · Cited by 40
Rosenstock, J., Yabe, D., Cox, D., Li, J., Denning, M., Wu, W.-S., Liu, R., Zhao, Y., Manghi, F. P., Abalos, F., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00202-3 · Cited by 50
Self-citationGong, B., Li, C., Shi, Z., Wang, F., Dai, R., Chen, G., & Su, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1675552 · Cited by 36
GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity
Cooper, M. E., & van Raalte, D. H. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194749 · Cited by 24
Kansakar, U., Jankauskas, S. S., Pande, S., Mone, P., Varzideh, F., & Santulli, G. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031409 · Cited by 22
“These observations align with clinical data from larger efficacy trials, including ACHIEVE-1 and ATTAIN studies, in which renal function remained stable throughout treatment despite substantial weight loss and glycemic improvement [27,45,47,62,69].”
InfluentialMuzurović, E. M., Katsiki, N., Volčanšek, Š., Plescia, F., Rizzo, M., & Mantzoros, C. S. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156494 · Cited by 25
Scragg, J., Koutoukidis, D. A., Dirksen, C., Heitmann, B. L., & Jebb, S. A. (2025) · Med · doi:10.1016/j.medj.2025.100805 · Cited by 16
Barana, L., De Fano, M., Cavallo, M., Manco, M., Prete, D., Fanelli, C. G., Porcellati, F., & Pippi, R. (2025) · Nutrients · doi:10.3390/nu18010131 · Cited by 13
Pharmacological therapies for type 2 diabetes: future approaches
Bailey, C. J. (2025) · Diabetologia · doi:10.1007/s00125-025-06581-6 · Cited by 28
SGLT-2 Inhibitors and GLP-1 Receptor Agonists as Combination Therapy in Type 2 Diabetes
Liakos, A., Karagiannis, T., Avgerinos, I., & Bekiari, E. (2026) · Current Diabetes Reports · doi:10.1007/s11892-025-01616-z · Cited by 21
GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease
Alicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-025-01036-y · Cited by 22
Novel oral agents in anti‐obesity pharmacotherapy: A narrative review
Buch, A., Eldor, R., Brown, R., & Zonszein, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16618 · Cited by 11
Pandey, R. K., Jan, M., Mohammad, A., Jawaid, K. A., Naveed, M., Abid, M. A., Amir, A. B., Ahmed, S., Safiullah, M., Bhatti, M. I., et al. (2025) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.70134 · Cited by 9
Obesity phenotypes and atherogenic dyslipidemias
Choe, H. J., Almas, T., Neeland, I. J., Lim, S. K., & Després, J. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70151 · Cited by 18
Hoffmann, K., Michalak, M., Rizzo, M., Maggio, V., & Paczkowska, A. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2586703 · Cited by 8
“One such innovation is oral GLP-1 receptor agonists like orforglipron – a non-peptide, once-daily agent currently under investigation – which may improve patient convenience and adherence compared to injectable formulations [51,52].”
Sonne, N., Roque, M., Zachariassen, L. F., Porsgaard, T., Pors, S. E., Cavalera, M., Jones, C., Osborn, O., Thorbek, D. D., Riis, M. L., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106121 · Cited by 9
Miramontes‐González, J. P., Rodrigo-Alaíz, Á., Gabella-Martín, M., Calle, D. G., Carretero-Gómez, J., & Corral-Gudino, L. (2026) · Diabetes Therapy · doi:10.1007/s13300-025-01829-1 · Cited by 11
Small-Molecule GLP-1 Receptor Agonists: A Promising Pharmacological Approach
Șeremet, O. C., Pușcașu, C., Andrei, C., Nițulescu, G., Zbârcea, C. E., & Olaru, O. T. (2025) · Medicina · doi:10.3390/medicina61111902 · Cited by 12
Chiang, C., Wang, K.-L., Cheng, H., Chao, T., & Sung, S. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001263 · Cited by 12
Patil, S., Jha, N., & Jha, M. K. (2026) · Addictive Behaviors Reports · doi:10.1016/j.abrep.2026.100671 · Cited by 24
Oral small-molecule GLP-1 receptor agonist for type 2 diabetes and obesity
Chow, E. W.-K., & Chow, E. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02381-5 · Cited by 7
Johnson, A. J., O’Sullivan, E. N., Valyasevi, P., Metras, B. N., Jang, S., Shields‐Cutler, R. R., Arlinghaus, K. R., Harindhanavudhi, T., & Teigen, L. M. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0219 · Cited by 11
CVOT Summit Report 2025: advances along the cardiovascular–kidney–metabolic disease continuum
Schnell, O., Agarwal, A., Azizi, M., Ballwieser, D. A., Barnard-Kelly, K. D., Battelino, T., Blüher, M., Bugianesi, E., Cebrián, A., Ceriello, A., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03140-0 · Cited by 6
iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.70167 · Cited by 5
Self-citationTantoush, M., Almaghrabi, Y., Abusbaeh, A., Ahmed, N., Tantush, A., Hamida, B. B., Sagher, M., Sager, M., Abouslima, A., Elbahnasawy, S. E., et al. (2026) · Cureus · doi:10.7759/cureus.102018 · Cited by 7
Lempesis, I. G., & Dalamaga, Μ. (2026) · Metabolism Open · doi:10.1016/j.metop.2026.100463 · Cited by 8
Weight maintenance after discontinuation of GLP-1 therapies
Moiz, A., Filion, K. B., Knäuper, B., Tsoukas, M. A., Brazeau, A.-S., Zolotarova, T., Lelièvre, A., & Eisenberg, M. J. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103992 · Cited by 7
“75–78 Aerobic training, while less effective for preserving lean mass, provides important complementary cardiovascular and psychological benefits.”
Islam, M. S., Monir, S. B., Haque, N., Vabna, M. A., Fan, J., Li, Y., Nime, I., Feroz, F., Acharjee, M., & Pan, F. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1710157 · Cited by 12
Ho, M. J., Liew, C. F., Tan, N. A. M. R., Morita, A., & Oon, H. H. B. (2026) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2026.2665732 · Cited by 7
Alper, A., Peleg, G., Fagin, A., Shah, P. P., Chowdhury, I. Z., Gonzales, A., & FAILLACE, R. T. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-025-00270-4 · Cited by 7
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101445 · Cited by 12
Self-citationGiorgino, F., DʼSOUZA, S., Ludwig, L., Kiyosue, A., Ibriga, H., RHA, H., Denning, M., Wu, W.-S., Landó, L. F., & Tobian, J. A. (2026) · JAMA · doi:10.1001/jama.2026.9512 · Cited by 8
Self-citationJamal, A., Khan, S., Qadri, M., Shah, A., Iftikhar, H., Fatima, E., Ahmad, M., Sikandar, M., Jawed, I., Muneeb, M., et al. (2026) · Acta Diabetologica · doi:10.1007/s00592-025-02635-8 · Cited by 3
Orforglipron: A Novel Oral GLP-1 Agonist for the Treatment of Obesity and Diabetes
Pillai, A. A., Sharma, A. M., Krayem, H., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001139 · Cited by 3
Welch, M., Forst, T. M., Jia, W., del Pino, P. O., Denning, M., Wu, W.-S., Li, J., Liu, R., EIFU, M., Chen, Y., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00800-7 · Cited by 7
Self-citationOrforglipron in type 2 diabetes mellitus and obesity: an overview
Panou, T., Gouveri, E., Popovic, D. S., & Παπάνας, Ν. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2594493 · Cited by 4
Hammad, N., Ramadan, A. M., Nazmy, A., Elazab, A., & Abdelaziz, A. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261420404 · Cited by 4
Pharmacologic Treatment of Obesity in the Context of Type 2 Diabetes
Conte, C., & Amaro, A. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01626-5 · Cited by 3
Kowalska, M. K., El‐Mallul, A., Hudecka, W., Lubojańska, J. E., Lubojański, P. J., Orłowska, S. M., & Bednarczyk, Ł. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27041886 · Cited by 10
Wang, Y., Feng, Z., & Yu, L. (2025) · The Innovation Medicine · doi:10.59717/j.xinn-med.2025.100150 · Cited by 2
Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes
(2025) · New England Journal of Medicine · doi:10.1056/nejmc2515117 · Cited by 2
Self-citationHageen, A. W., Gadelmawla, A. F., Saleh, A. O., Abdallfatah, A., Reyad, M., El‐Nemr, A. F., Maihoub, O., Elsekhary, A., Eladawi, S., Ayalew, B. D., et al. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70222 · Cited by 3
HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin: A Randomized Clinical Trial
Guo, L., Sun, Z., Zhang, L., Qin, G., Li, Y., Chen, X., Xu, N., Su, X., Li, M. T., Sun, J., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.15622 · Cited by 5
Cardiovascular Risk Reduction With GLP-1 RA Drugs
Pigeyre, M., & Gerstein, H. C. (2026) · Circulation · doi:10.1161/circulationaha.126.079319 · Cited by 4
Wharton, S., Stefański, A., Chen, J., Rao, G. S., Twum, E. A., & Denning, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71032 · Cited by 3
Self-citationKhachaturov, M., & Goulis, D. G. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70822 · Cited by 3
Mora, P., Aroda, V. R., Asong, M., Blüher, M., Carlander, A. F., Kaltoft, M., Vilsen, L. N., & Rosenstock, J. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01247-x · Cited by 4
Self-citationGLP ‐1 Receptor/Dual Agonists for Weight Loss: A Systematic Review and Network Meta‐Analysis of RCTs
Vienghirun, J., Sawangjit, R., Suttiruksa, S., Chaiyakunapruk, N., Jinathongthai, P., Khunti, K., & Lee, S. W. H. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70698 · Cited by 4
Arterburn, D. E., Curtis, L. H., Toh, S., Bradley, M. C., D’Alessio, D., Duchovny, N., Hines, D. W., Narain, K. D. C., Parekh, A., Skinner, A., et al. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-05468 · Cited by 3
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1445 · Cited by 1
Self-citationImpact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes
Baragetti, A., & Norata, G. D. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70483 · Cited by 1
Emara, A., Emara, M., Mansour, A., Elkholy, M., Abbas, O., Abdul‐Hafez, H. A., Azzawi, M. A. D. A., & Shubietah, A. R. M. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02218-9 · Cited by 1
Shirley, M. (2026) · Drugs · doi:10.1007/s40265-026-02363-5 · Cited by 3
Ntelis, S., & Wojeck, B. S. (2025) · Current Hypertension Reports · doi:10.1007/s11906-025-01349-0 · Cited by 1
Li, M., Fang, J., Qi, G., Guo, S., Xu, T., Lu, Y., Yuan, Q., Wang, J., Zhu, S., Shen, J., et al. (2026) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6c00077 · Cited by 3
Aroda, V. R., Davies, M. J., Maaske, J., Millegård, M., Juan, V. L., Aberle, J., Ciudin, A., McCrimmon, R. J., Eklund, O., Shih, J. L., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00802-0 · Cited by 6
Self-citationManaging Obesity in Individuals with Cardiovascular Disease: Are We Missing the Obvious?
Gao, M., Kurala, T. S., & Ajjan, R. (2026) · European Cardiology Review · doi:10.15420/ecr.2025.53 · Cited by 1
Li, L., Shui, D., Zhang, X., Tan, B., & Deng, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1854779 · Cited by 2
Lv, R., Peng, L., Xu, Y., Du, X., Liu, H. X., Wu, H., Zhang, Y., Li, Q., Jiao, X., Piao, C., et al. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.104045 · Cited by 3
Self-citationYabe, D., Shiraiwa, T., Ugai, H., Takeuchi, M., & Suzuki, R. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00138-5 · Cited by 1
Alper, A., Fagin, A., Karthikeyan, A., Karp, A., Terashima, R., Murli, H., Gershon, A., & FAILLACE, R. T. (2026) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-026-00814-4 · Cited by 1
Nicoletti, C. F., Lara, F. V.-O. D., & Martinez, J. A. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100690 · Cited by 2
Li, Y., Glotfelty, E. J., Parekh, P., Batsaikhan, B., Luo, W., Jackson, S. N., Harvey, B. K., & Greig, N. H. (2026) · Cells · doi:10.3390/cells15141301 · Cited by 2
Malhotra, A., Gottlieb, D. J., Kundel, V., Woehrle, H., Chakladar, S., GONCALVES, L. F., & Calamai, G. (2026) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2026.101660 · Cited by 3
Braha, A., Timar, B., Sturza, A., & Timar, R. Z. (2026) · Medicina · doi:10.3390/medicina62081509 · Cited by 2
Oral Glucagon-Like Peptide-1 Receptor Agonists for Preventing Cardiorenal Complications
Odeleye, V., Singh, N., Gautam, S., Shannon, E., Bibb, W. M., McClure, M., & Paul, T. K. (2026) · Current Cardiology Reports · doi:10.1007/s11886-026-02357-5 · Cited by 1
New Oral GLP-1 Receptor Agonists: Gliprons
Kim, C. (2025) · NeuroTrials · doi:10.65321/ntta.2025.002 · Cited by 1
Scheen, A. J. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00219-0 · Cited by 2
Paceana, M.-A., Mititelu-Tarțău, L., Boboc, I. K. Ş., Oancea, C. N., Berbecaru-Iovan, A., Foia, C. I., Tartau, C. G., & Bogdán, M. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18050620 · Cited by 1
Heisey, H. D., Gregg, L. P., Verrico, C. D., Villareal, D. T., & Fletcher, T. L. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70913 · Cited by 4
王, 钰. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.163787
Current diabetes drugs: Lessons learned and implications for next-generation therapeutics
Liao, J., Cong, Z., Liu, K., Que, H., & Liu, F. (2026) · The Innovation Drug Discovery · doi:10.59717/j.xinn-drugdisc.2026.100008
Beyond efficacy: the treatment lifecycle of incretin and multi-receptor agonists
Rabbani, S. A., El-Tanani, M., Matalka, I. I., & Rizzo, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1902185
The effect of GLP-1RAs and co-agonists on body composition across obesity and type 2 diabetes
Sun, L. L., Liu, H. F., Zhang, X., Zuo, F., Kong, Y., Feng, J., & Nian, X. (2026) · European journal of medical research · doi:10.1186/s40001-026-04534-2
Mazzone, P. M., Giacoppo, D., Ammirabile, N., Mauro, M. S., Spagna, F., & Capodanno, D. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag430
Han, Y., Shon, J., & Park, Y. J. (2026) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2026.2728313
Treatment potential of oral small-molecule GLP-1 receptor agonists
Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01135-9
Oral versus injectable GLP-1 receptor agonists in clinical practice
Curovic, V. R., & Rossing, P. R. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag101 · Cited by 1
Hageen, A. W., Gadelmawla, A. F., Saleh, A. O., Mohamed, M. R., Abdallfatah, A., Elsekhary, A., El‐Nemr, A. F., Eladawi, S., Maihoub, O., Abdulhay, H., et al. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70275
A novel unimolecular GLP1 and amylin receptor agonist for glucose and weight control
Chow, E., & Bai, Z. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01487-x
Yu, M., Peng, L., Jiang, C., Zhang, X., Li, Q., Zhang, L., Su, X., Zeng, Z., Yan, S., Wang, J., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04651-9 · Cited by 1
Peptidomimetics in GPCRs: From structural insights to clinical blockbusters
Li, G., Zhou, Q., & Wang, M. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.09.010 · Cited by 1
Chen, J. J., Chiru, E.-D., & Shen, S. (2026) · Current Breast Cancer Reports · doi:10.1007/s12609-026-00662-0
Chagas, G. C. L., Monteiro, M. R. L. M., EIRA, M. L., Chiappa, G. R., da Silva, J. C., & Abreu, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71397
iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · International Journal of Cardiovascular Sciences · doi:10.36660/ijcs.20260056
Self-citationCastro-Gamboa, J. A., Mora-Jiménez, J., Arguedas‐Chacón, S., & Zavaleta‐Monestel, E. (2026) · Cureus · doi:10.7759/cureus.110178
Laffin, L. J., Schlaich, M. P., Hall, M. E., Xie, C. C., Rao, G. S., Rettiganti, M., Dennehy, E. B., & Linetzky, B. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101783
Potential nephroprotective mechanisms of orforglipron, an oral non-peptide GLP-1 receptor agonist
Ramadurgum, P., Shah, J., Shah, E., & PALMER, B. F. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1917800
ACHIEVE-2: Orforglipron vs. Dapagliflozin bei unzureichend kontrolliertem Typ-2-Diabetes
Weiner, J. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01510-6
Glucagon-Like Peptide-1 Receptor Agonist-Associated Hepatotoxicity
Palmer, M. (2026) · Clinical Therapeutics · doi:10.1016/j.clinthera.2026.09.002
Cline, L., & Wilson, E. (2026) · Physician Assistant Clinics · doi:10.1016/j.cpha.2025.09.002 · Cited by 1
Patil, M., Piccinini, F., Johnstone, E. K. M., Casari, I., & Falasca, M. (2026) · Bioscience Reports · doi:10.1042/bsr20250114 · Cited by 1
GLP-1 Receptor Agonists: Emerging Indications, Limitations, and Future Directions
Kaur, S., Hevia, L. C., Lee, D., Mesdaq, H., Wong, J., Diallo, F., Anil, S., Gharibyar, N., & Gharibyar, S. (2026) · Pharmacology & Pharmacy · doi:10.4236/pp.2026.172003
Safety and tolerability of orforglipron in Japanese people with type 2 diabetes
Nauck, M. A., & Horowitz, M. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00182-8
Monnier, L., Schlienger, J.-L., & Colette, C. (2026) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2026.02.002
Klein, K. R., WYSHAM, C. H., Tuttle, K. R., Davies, M. J., Cox, D., Chen, J., Wu, W.-S., Denning, M., Liu, R., Ludwig, L., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01865-9 · Cited by 3
Self-citation
Metadata
- Authors
- Rosenstock, J., Hsia, S., Nevarez Ruiz, L., Eyde, S., Cox, D., Wu, W.-S., Liu, R., Li, J., Fernández Landó, L., Denning, M., Ludwig, L., & Chen, Y.
- Affiliations
- Medical City Dallas Hospital (US)
- Velocity Clinical Research (United States) (US)
- Hospital Angeles Chihuahua, Chihuahua, Mexico
- Eli Lilly (United States) (US)
- Eli Lilly, Indianapolis
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-09-18
- Volume
- 393
- Issue
- 11
- Pages
- 1065-1076
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4411506639
- Cited by
- 132
- References
- 15
- Citations by year
- 2026: 105 · 2025: 27
- FWCI
- 89.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- orforglipron, GLP-1 receptor agonists, type 2 diabetes, HbA1c, weight loss, weight management, dose comparison, early type 2 diabetes, treatment efficacy and safety, HbA1c reduction
- MeSH terms
- Glycemic Control, Glucagon-Like Peptide-1 Receptor Agonists, Administration, Oral, Adult, Aged, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Male, Middle Aged, Oxadiazoles, Fluorine Compounds
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.